| Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis. | |
| | |
MedLine Citation:
|
PMID: 10853875 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Nilvadipine, a calcium antagonist, has been shown to have antioxidant activity in vitro, but its effect on in vivo oxidation has not been assessed. The aim of this study was to investigate the antioxidant effect of this agent in vivo. The ratios of 7-keto cholestadien to cholesterol are believed to be an available marker of lipid peroxidation. Using these ratios, we have assessed the antioxidant effect of nilvadipine on low-density lipoprotein (LDL) in hypertensive patients with high risk of atherosclerosis. The risk factors of atherosclerosis may involve oxidation of LDL. METHODS: Fifteen healthy subjects (seven females and eight males aged 35-72 years, mean +/- SD = 55.3 +/-13.8 years) and fifteen hypertensive patients (seven females and eight males aged 45-80 years, mean +/- SD = 60.2 +/- 11.8 years) were recruited. Patients were treated orally with nilvadipine (4 mg b.i.d.) for 4 weeks. Cholesterol oxidation levels of LDL in patients before and after nilvadipine therapy and healthy subjects were studied. RESULTS: The ratios of 7-keto cholestadien to cholesterol in LDL of hypertensive patients before and 4 weeks after nilvadipine treatment and in healthy subjects were 6.5 +/- 1.6% (mean +/- SD), 3.8 +/- 1.2%, and 0.2 +/- 0.1%, respectively. There were significantly (P < 0.001) increased levels of cholesterol oxidation in LDL in patients with hypertension both before and after nilvadipine treatment compared with healthy subjects. However, there was a significantly (P < 0.001) decreased level of cholesterol oxidation in LDL in patients after nilvadipine treatment compared with patients before nilvadipine treatment. CONCLUSION: Our data showed that nilvadipine may protect LDL cholesterol from in vivo oxidation in hypertensive patients with high risk of atherosclerosis. |
| | |
Authors:
|
M Inouye; T Mio; K Sumino |
Related Documents
:
|
21931205 - Serum interleukin-23levels in patients with ulcerative colitis. 21719525 - Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (pai-1) promoter ... 22075505 - The effect of cyp2c9, vkorc1 genotypes and old age on warfarin pharmacologic sensitivit... 22760135 - Occurrence of dolichocolon without megacolon in chronic chagas disease patients. 2361835 - Management of children with short stature. 6606505 - Increased frequency of hla-dr3 and 5 in the syndromes of painless thyroiditis with tran... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: European journal of clinical pharmacology Volume: 56 ISSN: 0031-6970 ISO Abbreviation: Eur. J. Clin. Pharmacol. Publication Date: 2000 Apr |
Date Detail:
|
Created Date: 2000-10-03 Completed Date: 2000-10-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 1256165 Medline TA: Eur J Clin Pharmacol Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 35-41 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Hyogo Rehabilitation Center Hospital, Kobe, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antihypertensive Agents / pharmacology*, therapeutic use Arteriosclerosis / drug therapy, physiopathology Case-Control Studies Cholesterol, LDL / drug effects*, metabolism Female Humans Hypertension / drug therapy, physiopathology* Male Middle Aged Nifedipine / analogs & derivatives*, pharmacology, therapeutic use Oxidative Stress / drug effects*, physiology Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Cholesterol, LDL; 21829-25-4/Nifedipine; 75530-68-6/nilvadipine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evidence of clinical efficacy of homeopathy. A meta-analysis of clinical trials. HMRAG. Homeopathic ...
Next Document: Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual...